NIKKEI 225
38,125.64 -148.41 (-0.39%) HANG SENG
17,763.03 0.00 (0.00%) CRUDE OIL
79.20 +0.20 (+0.25%) GOLD FUTURES
2,335.00 +24.00 (+1.04%) DOW
37,903.29 +87.37 (+0.23%) Bitcoin GBP
45,988.48 -1,816.13 (-3.80%)
Novartis AG (NOVNN.MX)
- Yahoo Finance
CVS stock plunges after earnings numbers one analyst 'did not even believe'
CVS warns it could cede Medicare Advantage market share as reimbursement rates pressure the company.
- Globe Newswire
Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria
There is currently no evidence-based treatment for the smallest babies with malaria The CALINA study tested a new ratio and dose of Coartem® (artemether- lumefantrine) to account for metabolic differences in babies under 5 kg The CALINA trial indicated that the new formulation has good efficacy and safety, and the data have been submitted for regulatory review Basel, April 24, 2024 – Novartis and Medicines for Malaria Venture (MMV) announce positive data from their phase II/III CALINA study, dem
- Globe Newswire
Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors
Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17) and adult patients Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a rare cancer that is often unresectable and commonly diagnosed in the late stages of diseaseNovartis, a leader in radioligand therapy (RLT), is investigating a portfolio of RLTs to treat a broad range of cancers, including GEP-NETs, lung, prostate, breast, colon, bra
